The FDA approved Novo Nordisk’s once‑daily oral semaglutide (Wegovy pill), the first oral GLP‑1 authorized for weight loss in adults and approved for reducing major cardiovascular events in the label. Regulators signed off after phase 3 data showed clinically meaningful weight loss and cardiovascular benefit signals; Novo expects a U.S. launch in early January. Clinical data cited a top‑dose mean weight reduction of roughly 16.6% at 64 weeks versus placebo, narrowing the efficacy gap with weekly injectables. The approval opens a new commercial front in the obesity market by offering a pill alternative to injections, with implications for pricing, payer negotiations and patient access.